Patents Assigned to INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM)
-
Publication number: 20240228546Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.Type: ApplicationFiled: April 3, 2023Publication date: July 11, 2024Applicants: Institut National De La Sante Et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Ecole Normale Superieure De Lyon, Universite Claude Bernard Lyon 1Inventors: Théophile OHLMANN, Philippe MANGEOT, Emiliano RICCI
-
Publication number: 20240201185Abstract: The present invention is directed to methods of diagnosis and treatment of autoimmune, chronic inflammatory and lymphoproliferative diseases based on the identification of a population of pathogenic B and/or T cells showing a specific phenotype. These cells may be identified by their specific pattern of expression of marker proteins.Type: ApplicationFiled: April 21, 2022Publication date: June 20, 2024Applicants: SORBONNE UNIVERSITE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ASSISTANCE PUBLIQUE – HOPITAUX DE PARISInventors: Cindy MARQUES, Paul REGNIER, David SAADOUN
-
Publication number: 20240158797Abstract: An antisense oligonucleotides having the ability to decrease the expression level of the huntingtin protein in glioma cells, for their use in sensitizing the cells to an anti-cancer treatment.Type: ApplicationFiled: March 18, 2022Publication date: May 16, 2024Applicants: UNIVERSITÉ GRENOBLE ALPES, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), CENTRE HOSPITALIER UNIVERSITAIRE DE GRENOBLEInventors: Sandrine HUMBERT, Fabienne AGASSE, Frédéric SAUDOU, Kassem RAYANE
-
Publication number: 20240132547Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.Type: ApplicationFiled: April 2, 2023Publication date: April 25, 2024Applicants: Institut National De La Sante Et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Ecole Normale Superieure De Lyon, Universite Claude Bernard Lyon 1Inventors: Théophile OHLMANN, Philippe MANGEOT, Emiliano RICCI
-
Publication number: 20240131138Abstract: Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. The inventors produced an antibody that is directed against a surface antigen (i.e., CD40) of an antigen presenting cell (i.e., dendritic cell) wherein the heavy chain and/or light chain is conjugated to the MOMP VS4 domain of Chlamydia trachomatis for its use as vaccine.Type: ApplicationFiled: December 22, 2021Publication date: April 25, 2024Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hopitaux de Paris (APHP), Baylor Research Institute, Universite Paris Est Creteil Val De MarneInventors: Yves LEVY, Sylvain CARDINAUD, Mireille CENTLIVRE, Lydie DIEUDONNE, Sandra ZURAWSKI, Gérard ZURAWSKI
-
Publication number: 20240124532Abstract: Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. The inventors have set up candidate vaccines against Chlamydia trachomatis. In particular, the inventors have identified specific epitopes to be included in vaccine candidates thanks to in silico analysis of the amino-acid sequence of these proteins to map predicted MHC-I and -II epitopes by online software (NetMHC-4.0 and NetMHCII-2.3) and peptide binding prediction software. B cell epitopes were also mapped using online software (BepiPred-2.0 and Discotope). Finally, the inventors have generated some specific CD40 or Langerin antibodies comprising one or more identified epitope(s) of the present invention and that are suitable for vaccine purposes. Therefore, the present invention relates to Chlamydia trachomatis (Ct) antigenic polypeptides and uses thereof for vaccine purposes.Type: ApplicationFiled: January 28, 2022Publication date: April 18, 2024Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hopitaux de Paris, Universite Paris Est Creteil Val De Marne, Baylor Research InstituteInventors: Yves LEVY, Sandra ZURAWSKI, Gérard ZURAWSKI, Mireille CENTLIVRE, Lydie DIEUDONNE, Sylvain CARDINAUD
-
Publication number: 20240116923Abstract: The present invention relates to a compound of the following general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug for inhibiting ferroptosis.Type: ApplicationFiled: January 25, 2022Publication date: April 11, 2024Applicants: Seabelife, Centre National de la Recherche Scientifique (CNRS), Sorbonne Universite, Institut National de la Santé et de la Recherche Médicale (INSERM), Université Claude Bernard Lyon 1, Universite de Rennes 1Inventors: Stéphane BACH, Arnaud COMTE, Claire DELEHOUZE, Marie-Thérèse DIMANCHE-BOITREL, Peter GOEKJIAN
-
Publication number: 20240109940Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.Type: ApplicationFiled: November 22, 2023Publication date: April 4, 2024Applicants: Institut National De La Sante Et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Ecole Normale Superieure De Lyon, Universite Claude Bernard Lyon 1Inventors: Théophile OHLMANN, Philippe MANGEOT, Emiliano RICCI
-
Patent number: 11944616Abstract: The present invention relates to compounds of formula (I): for use as peripheral NMDA receptor antagonists.Type: GrantFiled: May 26, 2022Date of Patent: April 2, 2024Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ PARIS-SACLAY, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP), HOPITAL MARIE LANNELONGUEInventors: Sylvia Cohen-Kaminsky, Marc Humbert, Sebastien Dumas, Gilles Bru-Mercier, Samir Messaoudi, Jean-Daniel Brion, Mouad Alami, Gilles Galvani
-
Publication number: 20240100048Abstract: The success of anti-tumor immune responses requires effector T cells to infiltrate solid tumors, a process guided by chemokines. Herein, we demonstrate that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10, and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors for stabilizing the biologically active form of chemokines as a strategy to enhance tumor immunotherapy.Type: ApplicationFiled: December 7, 2023Publication date: March 28, 2024Applicants: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Rosa BARREIRA DA SILVA, Matthew ALBERT
-
Publication number: 20240091267Abstract: The present invention relates to an in vitro method for preparing a composition comprising mesenchymal stem cells (MSCs) intended for treating ischemia-reperfusion injury, comprising: a) providing MSCs; b) cultivating MSCs in a culture medium comprising a PPAR?/? agonist; c) removing the culture medium and washing the MSCs; and d) collecting MSCs in a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier does not contain a PPAR?/? agonist. It further relates to MSCs obtained using the method of the invention, as well as their use as a medicament, preferably in the treatment or prevention of ischemia-reperfusion injury, wherein the method of treatment or prevention does not comprise administering a PPAR?/? agonist to the subject.Type: ApplicationFiled: December 17, 2021Publication date: March 21, 2024Applicants: Universite de Montpellier, Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de MontpellierInventors: Farida DJOUAD SAMRI, Stéphanie BARRERE-LEMAIRE, Christian JORGENSEN
-
Publication number: 20240092858Abstract: The present invention relates to an expression cassette allowing expression of a functional LRIT3 protein in mammal eyes; said expression cassette is inserted in an expression vector, preferably an adeno-associated virus (AAV); accordingly, the present invention further relates to a recombinant adeno-associated virus (AAV) vector carrying a nucleic acid sequence encoding a normal LRIT3 gene, or fragment thereof, under the control of regulatory sequences which express the product of the gene in the ocular cells, a pharmaceutically acceptable composition comprising such a recombinant AAV vector and to its use for the treatment of congenital stationary night blindnessType: ApplicationFiled: December 8, 2020Publication date: March 21, 2024Applicants: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Christina Zeitz, Deniz Dalkara, Juliette Varin, Isabelle Audo, Serge Picaud, José-Alain Sahel
-
Publication number: 20240081729Abstract: A sleep analyzer, method and system with reduced invasiveness and limited human intervention to monitor sleep in an intensive healthcare unit.Type: ApplicationFiled: January 19, 2023Publication date: March 14, 2024Applicants: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), CENTRE HOSPITALIER UNIVERSITAIRE DE POITIERS, UNIVERSITE DE POITIERS, SOMNO ENGINEERING SASInventors: Xavier DROUOT, Maud Nicol DE LA BELLEISSUE
-
Patent number: 11919854Abstract: The present invention relates to compounds of formula (I), their enantiomers and their pharmaceutically acceptable salts, and their use in therapy, particularly for the treatment of cancer or inflammatory diseases.Type: GrantFiled: March 29, 2019Date of Patent: March 5, 2024Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CHRU DE LILLE, UNIVERSITE COTE D'AZUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE LILLE, JUNIAInventors: Valérie Vouret, Laetitia Douguet, Alina Ghinet, Germain Homerin, Benoît Guy Marie Rigo, Davy Jérémy Baudelet, Xavier Dezitter, Régis Millet, Christophe Furman
-
Patent number: 11913074Abstract: This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.Type: GrantFiled: March 17, 2023Date of Patent: February 27, 2024Assignees: PML Screening, LLC, The Université Paris-Saclay, The Assistance Publique—Hôpitaux de Paris (APHP), The Institut National de la Santé et de la Recherche Médicale (INSERM)Inventors: Eli Hatchwell, Peggy S. Eis, Edward B. Smith, III, Yassine Taoufik
-
Patent number: 11913073Abstract: This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.Type: GrantFiled: March 16, 2023Date of Patent: February 27, 2024Assignees: PML Screening, LLC, The Université Paris-Saclay, The Assistance Publique—Hôpitaux de Paris (APHP), The Institut National de la Santé et de la Recherche Médicale (INSERM)Inventors: Eli Hatchwell, Peggy S. Eis, Edward B. Smith, III, Yassine Taoufik
-
Patent number: 11905253Abstract: The present invention relates the field of reducing CD95-mediated cell motility in a subject, in particular for their use in the reduction of CD-95 mediated cancer cell motility, the reduction of CD95-mediated lymphocyte motility and/or B cell maturation, or the treatment of B-cell tumors, in a subject. The inventors identified a novel family of compounds having the ability to disrupt CD95/PLC?1 interaction and to neutralize the CD95-mediated calcium signaling pathway and cell migration in human peripheral blood lymphocytes (PBLs) and Th17 cells.Type: GrantFiled: April 19, 2019Date of Patent: February 20, 2024Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE RENNES 1, CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX, INSTITUT BERGONIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE BORDEAUXInventors: Pierre Vacher, Patrick Legembre, Mickael Jean, Patrick Blanco, Pierre Van De Weghe
-
Publication number: 20240053345Abstract: The present invention relates to a polypeptide X1X2-RK-X3X4-KK-X5X6X7X8X9X10-KR-X11X12 SEQ ID NO: 1 able to bind selectively to cells expressing proteoglycans comprising glycosaminoglycans as heparin or heparan sulfate. The linkage of said polypeptide to an internalization peptide enables the polypeptide to be internalized. The present invention further relates to a conjugated polypeptide comprising said polypeptide and a biomarker, to a cell penetrating polypeptide comprising said polypeptide, optionally a linker and a cell internalization peptide and a chimeric polypeptide comprising said cell penetrating polypeptide and one or more biological cargos.Type: ApplicationFiled: December 17, 2020Publication date: February 15, 2024Applicants: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ECOLE NORMALE SUPERIEURE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), COLLEGE DE FRANCEInventors: Sandrine Sagan, Alain Joliot, Astrid Walrant, Ludovic Carlier, Sébastien Cardon
-
Patent number: 11883398Abstract: The success of anti-tumor immune responses requires effector T cells to infiltrate solid tumors, a process guided by chemokines. Herein, we demonstrate that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10, and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors for stabilizing the biologically active form of chemokines as a strategy to enhance tumor immunotherapy.Type: GrantFiled: December 15, 2021Date of Patent: January 30, 2024Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Rosa Barreira Da Silva, Matthew Albert
-
Publication number: 20240010739Abstract: SARS-CoV-2 vaccines will be essential to reduce morbidity and mortality. The inventors produced an antibody that is directed against a surface antigen (i.e. CD40) of an antigen presenting cell (i.e. dendritic cell) wherein the heavy chain was conjugated to the receptor-binding domain of the Sars-Cov-2 spike protein for its use as vaccine. In particular, the inventors show that said vaccine induces circulating Ab-secreting hu-B cells, elicits S-specific IgG+ hu-B cells, elicits the expansion of central memory CD4+ hu-T cells and the emergence of effector memory CD4+ T cells, elicits the expansion of central memory CD8+ hu-T cells at and the emergence of effector memory CD8+ T cells at and finally induces Stem-cell like memory hu-CD8+ T cells.Type: ApplicationFiled: November 10, 2021Publication date: January 11, 2024Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hopitaux de Paris (APHP), Baylor Research Institute, Universite Paris Est Creteil Val De MarneInventors: Yves LEVY, Gérard ZURAWSKI, Mireille CENTLIVRE, Sandra ZURAWSKI, Véronique GODOT